Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C infection for at least 6 months duration~* Hepatitis C genotype 1a or 1b~* Participants must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study~* Participants showed a previous null response to therapy as defined by \< 2 logarithm to the base 10 (log10) international units per milliliter (IU/mL) decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV~Exclusion Criteria:~* Hepatitis C infection with a genotype other than genotype 1a or 1b~* Body mass index \< 18 or \>= 36 kilograms per square meters (kg/m\^2)~* Hepatitis A, hepatitis B, or human immunodeficiency virus (HIV) infection~* Herbal remedies \<=1 month prior to the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks) (Type: EXPERIMENTAL): Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
- TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks) (Type: EXPERIMENTAL): Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
- TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks) (Type: EXPERIMENTAL): Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
- TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks) (Type: ACTIVE_COMPARATOR): Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).